ClinicalTrials.gg
Enrolling by invitationNCT06768177Updated Oct 2, 2025

Platelet Rich Plasma (PRP) as Terapeutical Option in Erectil Disfunction (DE)

An interventional study of PRP injection and Alprostadil 20 micrograms in Erectile Dysfunction Due to General Medical Condition, Erectile Dysfunction Following Radical Prostatectomy and Erectile Dysfunction Associated With Type 2 Diabetes Mellitus, sponsored by Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari. Enrolling by invitation at 1 site in Italy. Open to male participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2025-10-02.

Sponsored by Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled Apr 2023, registered Dec 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
30 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing platelet rich plasma in Erectile Dysfunction — 2 open to participants now, 3 under way, none of them phase 3. platelet rich plasma · Erectile Dysfunction.

Planned enrollment
4th of 12
60 · median 60
Started
2023
with 1 other
No phase
3 of 12
1 open now
Registered
11th of 12
by date
Lead sponsor
1 of 12
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari

Among the 12 studies testing platelet rich plasma in Erectile Dysfunction, this one is the 4th largest by planned enrollment, is one of 2 that started in 2023, is one of 3 with no phase, and was the 11th registered.

Erectile Dysfunction

702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.

Browse Erectile Dysfunction studies →

Open to participants now

2 of the 12 studies testing platelet rich plasma in Erectile Dysfunction are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About platelet rich plasma

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 30 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing platelet rich plasma in Erectile Dysfunction, or all of them as a file.
02

Study summary

Patients are randomized into 2 groups (A and B), subsequently group A is subjected to a cycle of 6 weekly injections of 3 ml of autologous PRP while group B is subjected to 6 weekly injections of 1 ml of caverject (alprostadil) 20 mcg. After 4 (four) weeks the groups will be crossed, so group A will be subjected to 6 weekly injections of 1 ml of caverject (alprostadil) 20 mcg while group B will be subjected to a cycle of 6 weekly injections of 3 ml of autologous PRP.

03

Conditions studied

  • Erectile Dysfunction Due to General Medical Condition
  • Erectile Dysfunction Following Radical Prostatectomy
  • Erectile Dysfunction Associated With Type 2 Diabetes Mellitus
  • Erectile Dysfunctions

Browse trials for

04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Moderate to severe erectile dysfunction (IIEF-5 score below 17)
  • Patients previously treated with first- and therapies for ED
  • Patients who have undergone radical pelvic surgery with nerve sparing
  • Good pharmacological blood pressure control
  • Well-controlled diabetes on medication
  • Current or former smokers
  • Good renal function even with the use of medications
  • Well-controlled hypertriglyceridemia and/or hypercholesterolemia even with the use of medications
  • less than or equal to 35
  • Normal levels of FSH, LH, PRL, Total Testosterone, and TSH

Exclusion criteria

Exclusion Criteria:

  • Patients on antidepressant, anxiolytic, sedative, or antipsychotic medications.
  • Consumers of more than 500 g of alcohol per day.
  • greater than 35
  • Altered levels of FSH, LH, PRL, Total Testosterone, and TSH.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    TREATMENT ARM

    3 ML OF PRP

    Drug: PRP injection

  • Placebo comparator
    COMPARISON ARM

    CAVERJECT 1 ML

    Drug: Alprostadil 20 micrograms

Interventions

06

What researchers measure

Primary outcomes

  1. Change in erectile function

    Change in erectile function defined as the % of patients in each group achieving MCID in the IIEF-EF domain from baseline to 24 weeks (i.e. 12 weeks after the end of full treatment): * MCID (Minimal clinically important differences) is based on the severity of ED at baseline as: * Improvement of 5 or points more in IIEF score for patients with moderate ED (8-11) at baseline * Improvement of 2 or more points in IIEF score for patients with severe ED (5-7) at baseline

    Time frame: 24 WEEKS

Secondary outcomes

  1. EHS

    Time frame: change from baseline and at 8 weeks, 16 weeks, and 24 weeks Any value above 0 (0 = The penis does not enlarge)

    Time frame: 24 WEEKS

  2. The percentage of patients in each group who achieve MCID in the IIEF-EF domain from baseline after treatment with PRP

    MCID (Minimal Clinically Important Differences) is defined on the severity of ED at baseline as: * An improvement of 5 or more points in the IIEF score for patients with moderate ED (8-11) at baseline * An improvement of 2 or more points in the IIEF score for patients with severe ED (5-7) at baseline

    Time frame: 24 WEEKS

  3. The percentage of patients in each group who achieve MCID in the IIEF-EF domain from baseline after treatment with prostaglandin

    MCID (Minimal Clinically Important Differences) is defined on the severity of ED at baseline as: * An improvement of 5 or more points in the IIEF score for patients with moderate ED (8-11) at baseline * An improvement of 2 or more points

    Time frame: 24 WEEKS

  4. The difference in the IIEF score from baseline to the end of treatment between the PRP group and the prostaglandin-treated group.

    The difference in the IIEF score from baseline to the end of treatment between the PRP group and the prostaglandin-treated group.

    Time frame: 24 WEEKS

  5. SEP

    Change in SEP: * Response to questions 2 and 3 (SEP-Q2: Were you able to insert your penis into your partner's vagina? / SEP-Q3: Did your erection last long enough to allow you to have successful intercourse?) * Change from baseline (= "YES" response) o At T1 (2 weeks after the end of the first cycle), T2 (2 weeks after the end of the second cycle), and T3 (3 months after the end of the complete treatment)

    Time frame: 24 WEEKS

  6. GAQ

    Response to GAQ questions 1 and 2 (GAQ-Q1: Has the treatment you are taking improved your erectile function? / GAQ-Q2: If yes, has the treatment improved your ability to engage in sexual activity?) Change at T1 (2 weeks after the end of the first cycle), T2 (2 weeks after the end of the second cycle), and T3 (3 months after the end of the complete treatment) o Change from baseline (= "YES" response)

    Time frame: 24 WEEKS

  7. QEQ

    At T1 (2 weeks after the end of the first cycle), T2 (2 weeks after the end of the second cycle), and T3 (3 months after the end of the complete treatment) o Improvement of 2 or more in the score

    Time frame: 24 WEEKS

  8. Change in EDITS between PRP vs. prostaglandins

    At T1 (2 weeks after the end of the first cycle) and T2 (2 weeks after the end of the second cycle)

    Time frame: At T1 (2 weeks after the end of the first cycle) and T2 (2 weeks after the end of the second cycle)

  9. Change in TSS between PRP vs. prostaglandins

    Change in TSS between PRP vs. prostaglandins at T3 (3 months after the end of the complete treatment)

    Time frame: 3 months after the end of the complete treatment

  10. Change in SHIM

    Change in SHIM * At T1 (2 weeks after the end of the first cycle), T2 (2 weeks after the end of the second cycle), and T3 (3 months after the end of the complete treatment) * Improvement of 2 or more points in the score

    Time frame: 24 WEEKS

  11. ECDPD - Peak Systolic Velocity (PSV)

    ECDPD - Peak Systolic Velocity (PSV): * To assess penile hemodynamics from baseline to T1 (2 weeks after the end of the first cycle), T2 (2 weeks after the end of the second cycle), and T3 (3 months after the end of the complete treatment) * Recording of arterial penile velocity (cm/s) o Improvement in cm/s (any \> 30 cm/s)

    Time frame: 24 WEEKS

  12. ECDPD - Resistance Index (RI)

    ECDPD - Resistance Index (RI): * To assess penile hemodynamics from baseline to T1 (2 weeks after the end of the first cycle), T2 (2 weeks after the end of the second cycle), and T3 (3 months after the end of the complete treatment) * Penile vascular resistance index (ratio) o Improvement (any increase up to the normal value - 0.9)

    Time frame: 24 WEEKS

  13. ECDPD - End-Diastolic Velocity (EDV)

    ECDPD - End-Diastolic Velocity (EDV): * To assess penile hemodynamics from baseline to T1 (2 weeks after the end of the first cycle), T2 (2 weeks after the end of the second cycle), and T3 (3 months after the end of the complete treatment) * Recording of residual flow in a vessel at the end of the diastolic phase (cm/s) * Improvement in cm/s (any decrease in cm/s)

    Time frame: 24 WEEKS

  14. Adverse events

    Adverse events: Number of participants who experienced treatment-related adverse events. Defined as: skin reaction (e.g., swelling, erythema, and warmth), discomfort at the injection site, penile pain, change in penile appearance, new sexual problems, and any systemic reaction observed by investigators or concerns expressed by patients o At T1 (2 weeks after the end of the first cycle), T2 (2 weeks after the end of the second cycle), and T3 (3 months after the end of the complete treatment)

    Time frame: 24 WEEKS

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Nov 2024, 19 months.

Of 115 non-industry interventional studies with no phase under Erectile Dysfunction, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's 19 months is below that.

Counting every sponsor, half of 137 studies reached it within 32 months; a quarter within 14 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2024
First posted
Jan 10, 2025
StartActual
Apr 1, 2023
Primary completionActual
Nov 1, 2024
CompletionEst.
Nov 1, 2025
Last update
Oct 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06768177
Lead sponsor
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Responsible party
Sponsor
First posted
Jan 10, 2025
Start date
Apr 1, 2023
Primary completion
Nov 1, 2024
Completion
Nov 1, 2025 (estimated)
Last update
Oct 2, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Platelet rich plasma

Start the discussion